Letters to the EditorLOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATION
References (6)
Determination of debrisoquine and its 4-hydroxy-metabolite in biological fluids by gas chromatography with flame-isonization and nitro-selective detection
J Chromatogr
(1977)Polymorphic oxidation of debrisoquine and sparteine
Ethnic differences m drug metabolism
Clin Pharmacokinet
(1982)
Cited by (124)
The Irrelevance of In Vitro Dissolution in Setting Product Specifications for Drugs Like Dextromethorphan That are Subject to Lysosomal Trapping
2019, Journal of Pharmaceutical SciencesCitation Excerpt :One finding of this PBPK study is that the volume of distribution and clearance of the observed total metabolites corresponds best to the physicochemical properties of the glucuronide rather than the free DXO. Approximately 7% of white Europeans, 2% of black Americans,18 and less than 1% of Chinese and Japanese populations19 were found to be poor metabolizers (PM) of DEX. DEX undergoes O-demethylation by CYP2D6 into DXO as a primary metabolite, which further undergoes N-demethylation to 3-hydroxymorphinan by CYP3A4.
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
2016, Pharmacological ResearchCYP2D6 phenotypes and Parkinson's disease risk: A meta-analysis
2014, Journal of the Neurological SciencesCitation Excerpt :To provide an updated result on this topic and derive a more precise estimation of this relationship, we systematically reviewed and performed a meta-analysis to assess quantitatively the association between CYP2D6 gene polymorphisms and PD risk. The genetic background of CYP2D6 in Asian populations differs from that of Caucasians; Chinese people rarely (< 1%) have the biochemical PM phenotype [44], while Caucasians inherit 5–10% [45]. Therefore, we decided to perform the meta-analysis on Caucasians and to evaluate the most frequent genetic polymorphism site of CYP2D6 in order to determine whether a genetic polymorphism is associated with susceptibility to PD in this population.
Pharmacogenomics of CYP2D6: Molecular genetics, interethnic differences and clinical importance
2012, Drug Metabolism and PharmacokineticsPlasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients
2006, Progress in Neuro-Psychopharmacology and Biological PsychiatryDiverse Structures of Chimeric CYP-REP7/6-Containing CYP2D6 and a Novel Defective CYP2D6 Haplotype Harboring Single-type 36 and CYP-REP7/6 in Japanese
2006, Drug Metabolism and Pharmacokinetics